A randomized, double-blind study of the effect of Avastin [bevacizumab] plus gemcitabine and erlotinib compared with placebo plus gemcitabine and erlotinib on overall survival in patients with metastatic pancreatic cancer.
Latest Information Update: 27 Jul 2020
At a glance
- Drugs Bevacizumab (Primary) ; Erlotinib; Gemcitabine
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Registrational; Therapeutic Use
- Acronyms AVITA
- Sponsors Roche
- 13 Apr 2012 Trial status is recruiting in United kingdom as reported by European Clinical Trials Database record.
- 04 Oct 2010 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).
- 04 Jun 2009 Results have been presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO).